In 2000, the U.S. Food and Drug Administration (FDA) firstly approved ADC drug,Mylotarg®(gemtuzumab ozogamicin), for adults with acute myeloid leukemia (AML), which marked the beginning of ADC era of cancer targeted therapy.20By December 2021, there have been 14 ADC drugs approvals for ...
In this review, we summarize the preclinical studies in which ADCs are being used to target different antigens in pancreatic cancer, followed by a concise over- view of clinical trials that are assessing ADCs as a therapy for advanced pancreatic cancer. Lastly, we outline the challenges facing ...
Antibody therapeutics have revolutionized the treatment of cancer over the past two decades. Antibodies that specifically bind tumor surface antigens can b... S Panowski,S Bhakta,H Raab,... - 《Mabs》 被引量: 665发表: 2014年 Potent antibody drug conjugates for cancer therapy. Significant progr...
Antibody drug conjugate: the “biological missile” for targeted cancer therapy Article Open access 22 March 2022 Homogeneous multi-payload antibody–drug conjugates Article 17 May 2024 References Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody–drug conjugates: the la...
[1] Adam C. Parslow, Sagun Parakh, Fook-TheanLee.Antibody–Drug Conjugates for Cancer Therapy.Biomedicines.2016, 4, 14,2-17. [2] S Congreve, R Faris Elias, G Tidestav, VZafranian.Antibodydrug conjugates (ADC) Current ...
来源:2018,The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy 总之,ADC的结构设计在基于一定DAR的基础上,兼顾毒素活性、靶抗原亲和力、drug-linker结构的稳定性、低免疫原性、断裂方式等质量属性。改变ADC细分结构如配体单元...
Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatme...
[1] Adam C. Parslow, Sagun Parakh, Fook-TheanLee.Antibody–Drug Conjugates for Cancer Therapy.Biomedicines.2016, 4, 14,2-17. [2] S Congreve, R Faris Elias, G Tidestav, VZafranian.Antibodydrug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. ...
Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022). Article CAS PubMed PubMed Central Google Scholar Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–...
Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6:34–45. Article PubMed Google Scholar Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. ...